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infections in untreated patients = $31; moderate, AWIC = $287;
and severe, AWIC = $4182. CONCLUSION: These data show
IVIG prophylaxis cost $24,512 per patient year, compared to
$4500 with no prophylaxis, or about a 445% increase in cost.
The cost-effectiveness of IVIG in CLL has not been established,
and availability of IVIG is limited. Further studies on other
alternatives, such as prophylactic antibiotic therapy, and impact
on quality of life are needed.
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OBJECTIVE: There have been numerous studies on cost-
effectiveness of trastuzumab in both treatments of adjuvant and
metastatic breast cancer (BC). Nevertheless, the results reported
were varied depending upon the assumptions and/or perspectives
of the studies. We performed a systematic review of cost-
effectiveness-analysis (CEA) studies of trastuzumab in treatment
of HER2-postive breast cancer. METHODS: Literature search
from 1996 to December 2007 on databases including PubMed,
Ovid MEDLINE, and HealthSTAR was performed to retrieve
CEA studies of trastuzumab, using MESH terms and keywords
such as “trastuzumab,” “costs and cost analysis,” “economics,”
“breast neoplasm,” “cost effectiveness,” “cost utility,” and
“breast cancer.” Additionally, abstracts on CEA studies were also
obtained from American Society of Clinical Oncology (ASCO)
and ISPOR annual meetings. Only CEA studies reported incre-
mental cost-effectiveness ratio (ICER) or cost-utility ratio (ICUR)
as cost per quality-adjusted life years were included in this
review. RESULTS: Thirty ﬁve studies (20 published articles and
15 abstracts) were identiﬁed, of which 18 studies (14 adjuvant, 3
metastatic BC studies, and 1 study of product life-cycle of tras-
tuzumab) representing societal health care perspectives from 12
countries were satisﬁed the criteria. The mean (median) ICERs of
trastuzumab are $24,069/QALY ($23,766/QALY) [ranged from
$4,767 to $58,414/QALY] and $88,373/QALY ($80,000/QALY)
[ranged from $60,120 to $125,000/QALY] for HER2-postive
adjuvant and metastatic breast cancer treatments, respectively.
Majority of sensitivity analyses showed the main cost driver was
the acquisition cost of trastuzumab. In addition, over the product
life-cycle of trastuzumab, the overall ICER is $34,400/QALY
(Garrison et al., 2006). CONCLUSION: This review suggests
that the average costs per QALY of trastuzumab in both treat-
ments of adjuvant and metastatic HER2-positive breast cancer
are consistent and below the suggested cost effectiveness thresh-
old of $100,000/QALY.
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OBJECTIVE: To explore the cost-effectiveness of capecitabine as
adjuvant treatment for Stage III colon cancer. Phase III clinical
trials show that capecitabine improves disease-free survival.
However, these trials involved younger patients than reﬂected
clinically and overall survival was not signiﬁcantly better than
with usual care. We conducted a modeling study comparing
the cost-effectiveness of capecitabine and standard care
(Fluorouracil/Leucovorin (5FU/LV)) in a public-payer context
(Canada), using an older cohort, and with overall survival as the
main outcome. METHODS: A Markov model was developed
to determine the cost-effectiveness of capecitabine compared
with 5FU/LV. The base case was a 70-year-old man after total
mesorectal resection excision of Stage III colon cancer. A ﬁve
year time horizon was used. Health states included treatment
phase, remission, recurrence, disease progression, and death;
throughout the model (except during the active treatment states)
patients could die from other risk-related causes. Ontario health
economic data were used for costs. Probabilities were obtained
from the published literature, and sensitivity analyses were con-
ducted. RESULTS: The base case costs for capecitabine and
5FU/LV were $12,999 and $12,191, respectively. Overall sur-
vival was 4.132 and 4.069 years, respectively. The incremental
cost-effectiveness ratio of capecitabine was $12,821 per life year
gained. However, the incremental cost-effectiveness ratio of
capecitabine was greater than $50,000/life year when the annual
probability of relapse was greater than 0.96 or when drug costs
were assumed to be greater than $1410 per cycle (both values
within the plausible range). CONCLUSION: Capecitabine pro-
duced modestly improved survival over 5FU/LV (0.063 extra
years) with a favourable cost-effectiveness ratio. However,
because the model was sensitive to variations in relapse rate and
drug costs, the relative attractiveness of capecitabine over
5FU/LV is not certain. In addition, utilities and indirect costs
were not considered in the model. Because capecitabine is
administered orally, this could be an important factor warrant-
ing further research.
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OBJECTIVE: Compare two therapy regimens, Lapatinib plus
Capecitabine to Capecitabine alone, for advanced or Metastatic
HER2-positive breast cancer patients who were pretreated with
regimens that included an anthracycline, a taxane, and trastu-
zumab. METHODS: A Markov model, written in Microsoft
Excel(r), is used to simulate progression of breast cancer in a
hypothetical cohort of breast cancer patients in a societal per-
spective. The model consists of three health states: Clinical
Beneﬁts (Response or Stable Disease), Progressive Disease, and
Death. Transitions between health states were assumed to occur
once a month. Life expectancy, costs and QALYs are discounted
monthly by 0.0025% (3% annually). All costs are adjusted to
2007 dollars. RESULTS: Lapatinib plus Capecitabine increases
discounted life expectancy and quality-adjusted life expectancy
by 0.43 years and 0.54 years, respectively, when compared
to Capecitabine alone. This result yields an incremental cost-
effectiveness ratio (ICER) of USD$135,701.69 per QALY (upper
95% CI USD$230,864.99 per QALY), which may be cost effec-
tive, based on the threshold of USD$150,000/QALY. If the value
of Lapatinib price increases at least 13.4%, the combination
therapy is no longer cost-effective. The same outcome is observed
if we increase the transition probability from the Clinical Beneﬁts
state to the Progressive Disease state in the combination therapy
by 12.5% or if we decrease it by 19.3% in monotherapy.
Additionally, by using the 5th percentile of the utility for
Clinical Beneﬁts and the 95th percentile of the utility for
Progressive Disease, the ICER is US$D281,091.34/QALY and
USD$201,232.58/QALY, respectively. CONCLUSION: Based on
a threshold of USD$150,000/QALYs, the treatment with Lapa-
tinib plus Capecitabine is cost-effective in the base case for
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metastatic breast cancer patients. Although the mean of ICER is
USD$135,701.69, the upper limit 95% CI suggests that Lapa-
tinib plus Capecitabine may be cost-ineffective. In addition, for
reasonable changes in key parameters, the combination therapy
becomes cost-ineffective.
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OBJECTIVE: An earlier economic evaluation showed that sor-
afenib was cost-effective compared to best supportive care (BSC)
in advanced renal cell carcinoma (RCC) (ASCO 2006). Recently
latest overall survival data from the Phase III TARGET study
was presented (ASCO 2007). The objective of this study was to
update the earlier economic model with the latest clinical data to
evaluate the cost-effectiveness of sorafenib+BSC versus BSC alone
in advanced RCC from a United States payer perspective.
METHODS: A Markov model was developed to project lifetime
survival and costs associated with sorafenib+BSC and BSC alone.
The model tracked patients with advanced RCC through three
states—PFS, progression, and death. Transition probabilities
varied for each three-month period and were obtained from the
TARGET data. Treatment effectiveness wasmeasured in life-years
gained. Resource utilization included drug, administration, phy-
sician visits, monitoring, and adverse events. Costs and survival
beneﬁts were discounted annually at 3%. Univariate and proba-
bilistic sensitivity analyses were conducted. RESULTS: Lifetime
per patient costs were $92,222 and $36,634 for sorafenib+BSC
and BSC alone, respectively. The incremental survival beneﬁt
with sorafenib+BSC was 0.88 life years. The incremental cost-
effectiveness ratio (ICER) of sorafenib+BSC versus BSC alone was
$63,219 per LYG. Results were sensitive to variation in sorafenib
and BSC survival after progression as well as sorafenib cost. There
was a 95% probability that sorafenib would be cost-effective vs.
BSC alone, using a threshold of $95,000 or less. CONCLUSION:
Updating the model with the most recent clinical trial data still
resulted in an incremental cost-effectiveness ratiowithin the estab-
lished threshold that society is willing to pay for cancer care (i.e.
$50,000–$100,000 per LY). Thus, consistent with earlier ﬁndings,
sorafenib+BSC appears to be cost-effective in the management of
advanced RCC.
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Current cost-effectiveness models of prostate cancer prevention
treatments examine the cost-effectiveness of preventative treat-
ments from the perspective of patient populations speciﬁc to
the treatment’s clinical trial. However, factors such as age, race,
family history, and prostate-speciﬁc antigen (PSA) levels are
major predictors of patient risk for developing prostate cancer.
OBJECTIVE: To create a model that examines potential clinical
and economic beneﬁts of preventative treatments in various
patient populations as deﬁned by prominent risk factors that
can be used to identify populations who might most beneﬁt
from preventative treatments. METHODS: Similar to previ-
ously published cost-effectiveness models for preventative
prostate cancer treatments, we developed a Markov model con-
sidering health states such as cancer-free, low-grade prostate
cancer, high-grade prostate cancer, and death. We also consider
the impact of avoiding benign prostate hyperplasia (BPH) and
decreased quality of life due to treatment-related adverse events
such as erectile dysfunction. Unlike previous models, our model
incorporates prostate cancer nomograms developed from an
analysis of a clinical database of at-risk men to estimate the
probability of high and low-grade prostate cancer and recur-
rence. Nomograms consider age, race, family history, free-to-
total PSA levels, PSA levels, and DRE results. The model can
also consider incidence of prostate cancer by age and race as
seen in SEER and high-grade prostatic intraepithelial neoplasia,
family history, PSA levels, previous biopsy results, and BPH
and DRE results as obtained from an analysis of the European
Study of Screening for Prostate Cancer database. RESULTS:
The model generates cost-effectiveness ratios identifying condi-
tions where preventative treatment is most cost effective versus
no preventative treatment. Ratios also identify speciﬁc patient
populations where preventative treatment has an advantage.
CONCLUSIONS: The model can incorporate patient risk
factor diversity to generate cost-effectiveness ratios speciﬁc to
different epidemiological populations; thus, better targeting
populations who might beneﬁt most from preventative
treatments.
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OBJECTIVE: To assess the cost, effectiveness and cost-
effectiveness of three colorectal cancer (CRC) screening strate-
gies. METHODS: Simulation modeling was used to assess three
colorectal screening strategies of a virtual population over 50
years old: computed tomographic colonography (CTC), colonos-
copy and Fecal occult blood tests (FOBT). The model used a
simulation decision framework over a ten-years period. CTC is
repeated after 10 years if negative, and after three or ﬁve years if
positive with advanced or non-advanced adenoma respectively.
Colonoscopy is repeated after ten years if negative and after three
years or ﬁve years if positive with advanced or non advanced
adenoma respectively. FOBT is repeated every two years. Positive
CTC and FOBT are systematically conﬁrmed by colonoscopy.
The model computes the total cost and the incidence of CRC
after ten years of each screening strategy. RESULTS: Considering
a population adherence of 50%: colonoscopy being the only
screening strategy over 10 years is the most costly screening
strategy, €885 per individual, with 0.54% of remaining CRC.
CTC as only screening strategy over 10 years costs €543 per
individual with 0.18% of remaining CRC. FOBT as only screen-
ing strategy over 10 years costs €459 per individual with 0.18%
of remaining CRC. Mean cost-effectiveness ratios expressed as
cost-per-CRC-avoided are 544 with CTC, 890 with colonoscopy
and €460 with FOBT. CONCLUSION: This simulation model-
ing approach allows to take into account data variability and to
test various screening strategies. Further simulations have been
performed to study the impact of various screening program
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